Eribulin: all 134 studies that test it

Page 1 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingNCT07255612Phase 2
• A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingNCT07205185Phase 2
• Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingNCT06957431Phase 1
• Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
• Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNot yet recruitingNCT06308939Phase 2
• A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid TumorsRecruitingNCT06006273Phase 1
• Scalp Cooling in MBCRecruitingNCT04986579Phase 2
• Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast CancerTerminatedNCT05041101Phase 1/2Results posted
• A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasCompletedNCT03899805Phase 2Results posted
• Lenvatinib and Eribulin in Advanced Soft Tissue SarcomaCompletedNCT03526679Phase 1/2Results posted
• A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer PatientsTerminatedNCT03502681Phase 1Results posted
• Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)CompletedNCT03441360Phase 2Results posted
• Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)CompletedNCT03331250Phase 2Results posted
• Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid TumorsCompletedNCT03245450Phase 1/2Results posted
• Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesCompletedNCT03222856Phase 2Results posted
• ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.TerminatedNCT02681523Phase 2Results posted
• Eribulin and Lenvatinib in Advanced Solid TumorsCompletedNCT02640508Phase 2Results posted
• A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast CancerActive, not recruitingNCT02623972Phase 2Results posted
• Treatment of Brain Metastases From Breast Cancer With Eribulin MesylateCompletedNCT02581839Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerCompletedNCT02481050Phase 2Results posted
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by SurgeryCompletedNCT02178241Phase 2Results posted
• This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including LymphomasCompletedNCT02171260Phase 1Results posted
• Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerCompletedNCT02120469Phase 1Results posted
• Eribulin Mesylate in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedNCT02097238Phase 2Results posted
• Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line TreatmentCompletedNCT02061085Phase 2Results posted
• Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast CancerSuspendedNCT02037529Phase 3Results posted
• Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast CancerCompletedNCT01961544Phase 4Results posted
• An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid TumorsCompletedNCT01945710Phase 1Results posted
• Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerTerminatedNCT01912963Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast CancerCompletedNCT01908101Phase 2Results posted
• Eribulin in HER2 Negative Metastatic BrCaCompletedNCT01827787Phase 2Results posted
• Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast CancerCompletedNCT01705691Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical CancerCompletedNCT01676818Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland CancerCompletedNCT01613768Phase 2Results posted
• Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerCompletedNCT01596751Phase 1/2Results posted
• Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2CompletedNCT01593020Phase 2Results posted
• Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor MalignanciesCompletedNCT01554371Phase 1/2Results posted
• Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast CancerCompletedNCT01527487Phase 2Results posted
• Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast CancerTerminatedNCT01498588Phase 2Results posted
• An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)CompletedNCT01458249Phase 2Results posted
• A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT01454934Phase 3Results posted
• Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast CancerCompletedNCT01439282Phase 2Results posted
• A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast CancerCompletedNCT01432886Phase 1Results posted
• Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast CancerTerminatedNCT01388647Phase 1/2Results posted
• Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast CancerCompletedNCT01328249Phase 2Results posted
• Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue SarcomaCompletedNCT01327885Phase 3Results posted
• A Confirmation Study of Eribulin in Combination With CapecitabineCompletedNCT01323530Phase 1/2Results posted
• Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast CancerCompletedNCT01269346Phase 2Results posted
• A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast CancerCompletedNCT01268150Phase 2Results posted
• Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed TherapiesCompletedNCT01142661Not applicableResults posted
• Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder CancerTerminatedNCT01126749Phase 1/2Results posted
• Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung CancerCompletedNCT01126736Phase 1/2Results posted
• QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid TumorsCompletedNCT01106248Phase 1Results posted
• Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerCompletedNCT01104155Phase 2Results posted
• Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid TumorsCompletedNCT01000376Phase 1Results posted
• Study of E7389 for Advanced or Metastatic Breast CancerCompletedNCT00965523Phase 2Results posted
• A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid TumorsCompletedNCT00908908Phase 1Results posted
• A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerCompletedNCT00879086Phase 2Results posted
• Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh SystemCompletedNCT00706095Phase 1Results posted
• E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue SarcomaCompletedNCT00413192Phase 2Results posted
• E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00400829Phase 2Results posted
• E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00388726Phase 3Results posted
• Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer PatientsCompletedNCT00383760Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney DysfunctionActive, not recruitingNCT00365157Phase 1/2Results posted
• S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00337129Phase 2Results posted
• E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesCompletedNCT00337103Phase 3Results posted
• Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00337077Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00334893Phase 2Results posted
• Phase I Clinical Study of E7389CompletedNCT00326950Phase 1Results posted
• Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior ChemotherapyCompletedNCT00278993Phase 2Results posted
• A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and CapecitabineCompletedNCT00246090Phase 2Results posted
• Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet ChemotherapyCompletedNCT00100932Phase 2Results posted
• A Study of E7389 in Advanced/Metastatic Breast Cancer PatientsCompletedNCT00097721Phase 2Results posted
• Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid TumorsCompletedNCT00069277Phase 1Results posted
• Study of E7389 in Patients With Advanced Solid TumorsCompletedNCT00069264Phase 1Results posted
• Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerWithdrawnNCT06590558Phase 1
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Active, not recruitingNCT06382142Phase 3
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)Active, not recruitingNCT06343948Phase 3
• Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer PatientsStatus unknownNCT05833919Phase 2
• PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinActive, not recruitingNCT05810870Phase 2
• Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownNCT05546255Phase 2
• Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2
• Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast CancerStatus unknownNCT05402722Phase 2
• Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureTerminatedNCT05335473Phase 1/2
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast CancerTerminatedNCT05134194Phase 3
• Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast CancerStatus unknownNCT05033769Phase 4
• Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
• POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast CancerWithdrawnNCT04826016Phase 1/2
• Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerStatus unknownNCT04624711Phase 2
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingNCT04579224Phase 3
• Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT04517292Phase 2
• Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsStatus unknownNCT04502680Phase 2
• A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCStatus unknownNCT04303741Phase 2
• A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingNCT04078295Phase 1/2
• Eribulin in Advanced Solitary Fibrous TumorCompletedNCT03840772Phase 2
• A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or LeiomyosarcomaCompletedNCT03810976Phase 2
• Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer PatientsTerminatedNCT03795012Phase 2
• Eribulin in Brain Metastases From HER2-negative Breast CancerWithdrawnNCT03637868Phase 2

← Eribulin overview